The Vehicle, Spring 2006

Table of Contents Inicio de TerminoJacob Fosterpage 1 Devoted FriendMaurice Tracypage 2 Bad Hair DaysGreg Coreypage 2 Shelf LifeJody Shootpage 3 AnointMaurice Tracypage 4 Understanding BlackAmanda Bushpage 5 My Uncle\u27s HouseCarissa Haydenpage 7 Try, And Save Your BreathGreg Coreypage 8 Solid AdviceAnthony Shootpage 8 Calligraphy / The Metamorphosis / Buttercup DragonflyGrey Harrellpage 9 Swinging FireMaurice Tracypage 11 Epitaph for a Man With No Name 1860-1892Dallas Schumacherpage 12 Untitled 71Ben Hartpage 13 Random Maunderings of a Ford Hall InsomniacJacob Fosterpage 14 Fat BangsLakisha Allenpage 15 I WantMaurice Tracypage 16 DiscoveryCarissa Haydenpage 17 Poverty SpongeChris Robinsonpage 18 Seedless GrapesAnthony Shootpage 19 Untitled 34Ben Hartpage 20 DiscoveryCarissa Haydenpage 21 drunk againAnthony Shootpage 22 SquareMaurice Tracypage 23 Let Me Just Say ThisJody Shootpage 24 passing a small cemetery after a stormAnthony Shootpage 25 Career DayMitch Jamespage 26 Art Submissions Beaded VaseBrandy Lee Bartercover The StrayBrandy Lee Barterpage 10 RapidsKristy Van Amerongenpage 10 UntitledKristy Van Amerongenpage 13 UntitledKristy Van Amerongenpage 15 A Quiet RoadBrandy Lee Barterpage 19 X Marks the SpotBrandy Lee Barterpage 20 An Old FriendBrandy Lee Barterpage 25 The Vehicle Staffpage 27 Contributorspage 28https://thekeep.eiu.edu/vehicle/1085/thumbnail.jp

White Matter Hyperintensities in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Knowledge Gaps and Opportunities

White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small vessel disease, WMHs are associated with increased likelihood of cognitive impairment and dementia (including Alzheimer\u27s disease [AD]). WMHs are also seen in cognitively healthy people. In this collaboration of academic, clinical, and pharmaceutical industry perspectives, we identify outstanding questions about WMHs and their relation to cognition, dementia, and AD. What molecular and cellular changes underlie WMHs? What are the neuropathological correlates of WMHs? To what extent are demyelination and inflammation present? Is it helpful to subdivide into periventricular and subcortical WMHs? What do WMHs signify in people diagnosed with AD? What are the risk factors for developing WMHs? What preventive and therapeutic strategies target WMHs? Answering these questions will improve prevention and treatment of WMHs and dementia

Ocular delivery of acetylsalicylic acid by repetitive coulomb-controlled iontophoresis

To investigate the potential of transscleral coulomb-controlled iontophoresis (CCI) for repetitive delivery of acetylsalicylic acid (ASA) into the eye, a total of 50 rabbits was included in this study. Fourteen animals received serial CCI treatment. Fourteen animals underwent CCI with either ASA or balanced salt solution (BSS) for at least 6 days at 24- and 48-hour intervals. Eighteen animals received a single CCI application, while 18 animals were injected with 15 mg ASA/kg body weight intravenously. HPLC analysis was performed to determine the levels of salicylic acid (SA) in ocular tissues. Apart from clinical follow-up, 2 rabbits in the ASA and BSS groups were examined by electroretinography, and 2 animals were examined histologically. Though high concentrations of SA were measured, no alterations were observed clinically, histologically and electrophysiologically. Repetitive CCI demonstrated its potential as a topical drug delivery system for ASA into the eye. This transscleral delivery of ASA resulted in significant and sustained intraocular concentrations of SA without side effects. Iontophoresis may be advantageous in clinical administration maintaining therapeutic levels of ASA while avoiding adverse effects associated with the systemic administration of nonsteroidal anti-inflammatory drugs

Pharmacokinetics of Systemic Versus Focal Carboplatin Chemotherapy in the Rabbit Eye: Possible Implication in the Treatment of Retinoblastoma

PURPOSE. To characterize the pharmacology and toxicity of intravenous versus focal carboplatin delivery in the rabbit eye. METHODS. Pharmacological distribution of carboplatin was examined in New Zealand White Rabbits after a single intravenous infusion of carboplatin (18.7 mg/kg of body weight), a single subconjunctival carboplatin injection (5.0 mg/400 L), or a single application of carboplatin delivered by Coulombcontrolled iontophoresis (CCI; 14 mg/mL carboplatin, 5.0 mA/ cm 2 , 20 minutes). After each treatment, animals were euthanatized, and the eyes analyzed at 1, 2, 6, or 24 hours by atomic absorption spectroscopy to determine carboplatin concentration in ocular structures. Potential toxicity of focally delivered carboplatin was assessed by histology after six cycles of 5.0 mg carboplatin delivered by subconjunctival injection or six transscleral carboplatin CCI applications at 72-hour intervals (14.0 mg/mL, 20 minutes at 2.5 mA). RESULTS. Determination of concentrations through atomic absorption spectroscopy in the retina, choroid, vitreous humor, and optic nerve after subconjunctival injection or iontophoretic carboplatin delivery revealed significantly higher levels than those achieved with intravenous administration. Carboplatin concentrations in the blood plasma were found to be significantly higher after intravenous delivery than after focal delivery by subconjunctival injection or CCI. No evidence of ocular toxicity was detected after focally delivered Carboplatin. CONCLUSIONS. Focal administration of carboplatin using subconjunctival or noninvasive CCI safely and effectively transmits this chemotherapeutic drug into the target tissues of the retina, choroid, vitreous, and optic nerve. These results suggest that focal carboplatin delivery may effectively increase intraorbital carboplatin concentrations while decreasing systemic exposure to this cytotoxic drug. (Invest Ophthalmol Vis Sci